Wake Forest Recognition

Pictured above (left to right): Kamara Mertz-Rivera, Amy Curtis MD, Christine Greene, Jeremy Kilburn MD

We’re proud to share that UC-NCORP was honored as one of the top NCORP sites for patient accruals at the recent Wake Forest annual meeting. This recognition highlights the dedication and hard work of our research teams in advancing cancer care through clinical trials.

A special congratulations goes to Dr. Michael Humeniuk, who received individual recognition for his high accruals to NCORP Cancer Care Delivery Research (CCDR) trials. His commitment to improving patient outcomes through research continues to inspire.

Newly Activated Studies

These studies have recently activated.

More information can be found on CTSU.

EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
A092204: A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
AEWS2431: Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Research Base Meetings

Alliance Fall Meeting: November 5-7, 2025 - Chicago, IL

NRG Winter Meeting: January 22-26, 2026 - San Francisco, CA

ECOG-ACRIN Spring Meeting: May 5-7, 2026- Philadelphia, PA

Accruals, Biospecimens, & Special Entries

Under-Represented Populations

CCDR Corner

All About AYAs

Diving In!

This October, the American Cancer Society (ACS) commemorates the 40th anniversary of Breast Cancer Awareness Month. In 1985, ACS co-led the effort to start Breast Cancer Awareness Month as a week-long campaign to educate women about the importance of early screening and routine mammograms for breast cancer detection and treatment.

For the past four decades, ACS researchers and scientists have been an integral part of breast cancer breakthroughs:

1980s-1990s BRCA1 and BRCA2 genes are discovered, and the FDA approves the drug Herceptin.

2000s Breast cancer stem cells are identified.

2010s Triple-negative breast cancer immunotherapy approved.

2020s mRNA-based breast cancer vaccines show promise, and liquid biopsies projected to expand.

According to the ACS’s Cancer Facts & Figures 2025 report, approximately 1 in 8 women in the U.S. will be diagnosed with invasive breast cancer during their lifetime, and 1 in 43 will die from the disease. However, there has been tremendous progress; ACS researchers project that by 2035, the number of breast cancer survivors will reach 5.3 million.

Today, ACS encourages everyone to turn awareness into action in the continued mission of ending breast cancer as we know it. With early detection being a critical factor in successful breast cancer treatment, developing robust community-engaged health promotion efforts is essential to promote breast cancer screening and navigate complex treatment options (Dean et al., 2018). Engaging with a range of communities ensures that the information about breast cancer screening and treatment options and the promotion efforts for breast cancer awareness month are inclusive of the needs of all women, regardless of racial and ethnic background, which is critical to any effective policy or practice change efforts (Gehlert et al., 2021).

To combat the disease and support both individuals and their families going through a diagnosis, ACS funds research that advances prevention and treatment efforts, advocates for equitable access to care, and provides programs, services, and science-based cancer information, helping to ensure that no one faces breast cancer—or any cancer—alone.

This October… always remember to Know Risk Factors, Get Yearly Mammograms, Make Healthy Lifestyle Choices & Learn About Clinical Trials!

Smiling Faces

UC-NCORP had great representation at the ECOG-ACRIN Semi-Annual meeting this month!